Drug intelligence / Profile preview

prusogliptin

Development stage: Phase 3
Lead developer: CSPC Ouyi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Prusogliptin is an orally active, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type 2 diabetes mellitus. Originally discovered by the Development Center for Biotechnology (DCB) in Taiwan and subsequently licensed to CSPC Ouyi Pharmaceutical, the drug functions by inhibiting the DPP-4 enzyme, which is responsible for the rapid degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging the activity of these hormones, prusogliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby improving glycemic control. In May 2024, the National Medical Products Administration (NMPA) of China approved prusogliptin for the treatment of type 2 diabetes, marking its first global regulatory approval.

Brand names: Enli
Other names: prusogliptin phosphate

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on prusogliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prusogliptin.

Explore the full profile